A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004.
Bekker
Pirow J
PJ
Holloway
Donna L
DL
Rasmussen
Amy S
AS
Murphy
Robyn
R
Martin
Steven W
SW
Leese
Philip T
PT
Holmes
Gregory B
GB
Dunstan
Colin R
CR
DePaoli
Alex M
AM
D000911:Antibodies, Monoclonal / Q000266:history / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002352:Carrier Proteins / Q000276:immunology; D000069448:Denosumab; D005260:Female; D049674:History, 21st Century; D006801:Humans; D008562:Membrane Glycoproteins / Q000276:immunology; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000266:history; D053245:RANK Ligand; D016032:Randomized Controlled Trials as Topic; D053246:Receptor Activator of Nuclear Factor-kappa B
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D002352:Carrier Proteins; D008562:Membrane Glycoproteins; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; C505686:TNFRSF11A protein, human; C505688:TNFSF11 protein, human; D000069448:Denosumab